Theratechnologies año OPV
¿Qué es el año OPV de Theratechnologies?
El año OPV de Theratechnologies, Inc. es 1996
¿Cuál es la definición de año OPV?
La oferta pública inicial es un tipo de oferta pública en la cual las acciones de una compañía generalmente se venden a inversionistas institucionales que, a su vez, venden al público en general, en una bolsa de valores, por primera vez.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
año OPV de compañías en Sector Health Care en TSX en comparadas con Theratechnologies
¿Qué hace Theratechnologies?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Empresas con año opv similar a Theratechnologies
- Shaw Communications tiene año OPV de 1995
- Husky tiene año OPV de 1995
- Transcontinental , Cl B Mv tiene año OPV de 1995
- Mountain Inc tiene año OPV de 1995
- Brookfield Asset Management tiene año OPV de 1995
- ShawCor tiene año OPV de 1995
- Theratechnologies tiene año OPV de 1996
- BXP tiene año OPV de 1997
- Faro Technologies tiene año OPV de 1997
- Silgan tiene año OPV de 1997
- Warrior Gold tiene año OPV de 1997
- Ryanair Plc tiene año OPV de 1997
- SIGA Technologies Inc tiene año OPV de 1997